Business Wire

New CSC Research Finds Over 90% of Websites Linked to Donald Trump and Joe Biden Campaigns at Risk for Potential Redirection, Disinformation, and Data Theft

8.10.2020 13:00:00 EEST | Business Wire | Press release

Share

CSC, a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division that reveals areas of risk for prominent election-related websites. The research indicates that web domains closely linked to the campaign websites for Joe Biden and Donald Trump lack basic domain security protocols and are being targeted for disinformation activities such as domain spoofing, and threats including domain name and domain name system (DNS) hijacking, and phishing.

On the heels of its recent Forbes Global 2000 research, CSC is seeing major risks related to the manipulation of web properties that voters rely on for information and donations. Findings show that over 90% of these web properties are not using registry locks to protect their domains from domain and DNS hijacking that can lead to phishing attacks, network breaches, and email compromise.

“As noted in our previous research, we’ve consistently seen domains emerge as a threat vector for enterprises, and an area that is continuously overlooked in cyber security. Due to the sensitivity and importance of the U.S. election process, domain security remains a major vulnerability for the potential of foreign interference, fraud, and misinformation,” says Mark Calandra, executive vice president for CSC DBS. “As an organization with the most visibility into the domain landscape, we advocate for the sanctity of voter trust and encourage both presidential candidates and other websites in the electoral ecosystem to prioritize domain security on their websites to ensure security and build confidence.”

"We have reached the point where awareness is not enough. Those responsible for managing domain registrations, including registrars and hosting companies, need to have an actionable plan that is aligned with best practices. Additionally, experiences must be shared between those within the industry for the good of the wider internet community," said Matthew Stith, industry liaison at Spamhaus. “Without this commitment, users will be open to continued manipulation and fraud."

In April of 2020 when domain names were at the center of many COVID-19 related fraud schemes, Senators Mazie K. Hirono (D-Hawaii), Cory Booker (D-N.J.), and Maggie Hassan (D-N.H.) called on domain name registrars and hosting sites to combat scams and misinformation. CSC’s research shows that domain security and preventing domain spoofing continue to be an oversight even with top election-related web properties. Our research shows that more than 75% of these election-related domains are using retail-grade domain registrars, which do not provide advanced security protocols.

Our research also showed that, of the typo domains related to joebiden.com and donaldjtrump.com, 60% are still available for registration, thereby posing future threats. Additionally, more than a third of those presidential candidate typo domains are linked to third parties; of that one third, nearly 70%:

  • Are configured to send and receive emails, which can be used to lure donors to phishing sites
  • Were registered in 2020 leading up to the November election
  • Disguise the owner’s identity behind proxy or privacy services

With cyber criminals subverting activities on these websites to disseminate misinformation or commit fraud against web visitors, there is also the threat of ransomware. Simon Chassar, chief revenue officer at NTT Ltd.’s Security division states, "NTT's September Monthly Threat Report identified ransomware as a significant threat to the U.S. election infrastructure. With DNS, domains, and email being a potential vehicle to distribute malicious content, our NTT Ltd. Security division suggests focus in this area, ensuring it is secure by design."

For additional details on these findings, visit the CSC blog “U.S. Election-Related Web Properties Prone to Fraud and Misinformation Due to Lack of Domain Security.”

Note: CSC aggregated this data using SimilarWeb.com for the period of August 1 – August 30, 2020.

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information:
Christine Blake
W2 Communications
703-877-8114
CSC@w2comm.com
CSC® News Room

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye